BACE1 and early-onset autosomal dominant Alzheimer disease: As a method of treatment, AAV-mediated delivery of Nbs into the brain has also been evaluated, namely for the Nb targeting BACE1 (beta-secretase 1), a target in Alzheimer’s disease (67).